Global S&T Development Trend Analysis Platform of Resources and Environment
DOI | 10.1126/science.abg8663 |
Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes | |
Chadi M. Saad-Roy; Sinead E. Morris; C. Jessica E. Metcalf; Michael J. Mina; Rachel E. Baker; Jeremy Farrar; Edward C. Holmes; Oliver G. Pybus; Andrea L. Graham; Simon A. Levin; Bryan T. Grenfell; Caroline E. Wagner | |
2021-04-23 | |
发表期刊 | Science
![]() |
出版年 | 2021 |
英文摘要 | For two-dose vaccines against severe acute respiratory syndrome coronavirus 2, some jurisdictions have decided to delay the second dose to rapidly get the vaccine into more people. The consequences of deviating from manufacturer-prescribed dosing regimens are unknown but will depend on the strength of immune responses to the vaccines. Saad-Roy et al. took a modeling approach to tackling the inevitable uncertainties facing vaccine rollout. The authors found that although one-dose strategies generally reduce infections in the short term, in the long term, the outcome depends on immune robustness. A one-dose strategy may increase the potential for antigenic evolution if immune responses are suboptimal and the virus continues to replicate in some vaccinated people, potentially leading to immune-escape mutations. It is critical to gather serological data from vaccinated people and, to avoid negative outcomes, to ramp up vaccination efforts worldwide.
Science , this issue p. [363][1]
### INTRODUCTION
As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues, the deployment of safe and effective vaccines presents a key intervention for mitigating disease severity and spread. Numerous logistical challenges and shortages have emerged alongside the international distribution of approved vaccines. In response, several countries have chosen to delay the second dose in an effort to increase the number of individuals receiving at least one dose. A key question then becomes how the timing of delivery of the second dose will affect future epidemiological and evolutionary outcomes.
### RATIONALE
We build on an existing immuno-epidemiological framework that assumes that, without vaccination, individual immunity after recovery from primary infection may eventually wane, leading to (a potentially reduced) susceptibility to secondary infections. To explore epidemiological outcomes, we extend the model to incorporate two vaccinated classes, corresponding to individuals who have received either one dose or two doses of a SARS-CoV-2 vaccine. As with natural immunity, we allow for one- or two-dose vaccinal immunity to wane, and we consider a continuous spectrum for the interdose period between vaccines. To reflect the increase in available doses resulting from a delayed second dose, we model the rate of administration of the first dose as an increasing function of the interdose period. We then consider evolutionary outcomes by coupling this framework to a simple phylodynamic model for potential viral adaptation under different evolutionary scenarios, each with its own assumptions regarding viral abundance and within-host selection for the different partially susceptible classes.
### RESULTS
We find that delaying second vaccine doses reduces COVID-19 infections in the short term by increasing the proportion of immune individuals. In the longer term, however, both the infection burden and the relative potential for viral adaptation are highly dependent on the robustness of natural or vaccinal immune responses. Notably, we find that even if immunity conferred by a single vaccine dose is poor, starting with a one-dose policy early on to increase the number of individuals immunized and then switching to the manufacturer-recommended two-dose regime as vaccine capacity increases can mitigate potential negative longer-term epidemiological and evolutionary outcomes. This mitigation can also be achieved by ramping up overall vaccination rates as availability improves.
### CONCLUSION
The deployment of SARS-CoV-2 vaccines will strongly shape postpandemic epidemiological trajectories and characteristics of accumulated population immunity. Our models show that the combination of different vaccine dosing regimes and variations in the robustness of natural and vaccinal immunity may result in a wide range of potential epidemiological and evolutionary outcomes in the medium term. It is therefore imperative to determine the strength and duration of clinical protection and transmission-blocking immunity through careful clinical evaluations in order to enforce sound public policies. In places where vaccine deployment is delayed and vaccination rates are low, our results stress the subsequent negative epidemiological and evolutionary impacts that may emerge. Particularly because these consequences (for example, the evolution of new variants) could emerge as global problems, there is an urgent need for global equity in vaccine distribution and deployment.
![Figure][2]
The relative robustness of one- or two-dose vaccinal immunity and natural immunity shape future epidemiological and evolutionary outcomes for SARS-CoV-2.
An immuno-epidemiological model (left) coupled with a phylodynamic model (middle) is used to explore projections for COVID-19 infection burden and immune landscapes (top right) and potential rates of SARS-CoV-2 viral adaptation (bottom right) in the medium term. The accompanying online interactive application ( |
领域 | 气候变化 ; 资源环境 |
URL | 查看原文 |
引用统计 | |
文献类型 | 期刊论文 |
条目标识符 | http://119.78.100.173/C666/handle/2XK7JSWQ/324075 |
专题 | 气候变化 资源环境科学 |
推荐引用方式 GB/T 7714 | Chadi M. Saad-Roy,Sinead E. Morris,C. Jessica E. Metcalf,et al. Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes[J]. Science,2021. |
APA | Chadi M. Saad-Roy.,Sinead E. Morris.,C. Jessica E. Metcalf.,Michael J. Mina.,Rachel E. Baker.,...&Caroline E. Wagner.(2021).Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes.Science. |
MLA | Chadi M. Saad-Roy,et al."Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes".Science (2021). |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论